Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
estriol + glatiramer acetate
- Development stage
- Phase 2
- Lead developer
- Theriva Biologics
- Modality
- Small Molecules
- Administration
- Oral, Injectable
01
Overview
A combination therapy consisting of oral estriol and injectable glatiramer acetate for the treatment of relapsing-remitting multiple sclerosis in women. Estriol is a pregnancy hormone with anti-inflammatory and neuroprotective properties, while glatiramer acetate is an established disease-modifying therapy that modulates immune processes involved in MS pathogenesis. The combination has shown promise in reducing relapse rates compared to glatiramer acetate alone.
02
Targets
Beyond the preview
Go deeper on estriol + glatiramer acetate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on estriol + glatiramer acetate.